Type 1 interferonopathy
MONDO:0700264Conditions in which increased type 1 interferon signaling leads to autoimmune and neurological disorders. These disorders are caused by variants in genes involved in nucleic acid metabolism, sensing, and the innate immune response.
31 clinical trials for this condition and its sub-types, 4 tagged with Type 1 interferonopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Type 1 interferonopathy
-
Type 1 interferonopathy of childhood 0 trials · 19 incl. sub-types
12 sub-types
- Aicardi-Goutieres syndrome 9 trials Sub-types →
- Autoimmune interstitial lung disease-arthritis syndrome 3 trials Sub-types →
- Deficiency of adenosine deaminase 2 3 trials
- Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations 3 trials
- STING-associated vasculopathy with onset in infancy 2 trials
- Familial chilblain lupus 2 trials Sub-types →
- Proteosome-associated autoinflammatory syndrome 2 trials Sub-types →
- Singleton-Merten dysplasia 1 trial Sub-types →
- Spondyloenchondrodysplasia with immune dysregulation 0 trials
- X-linked reticulate pigmentary disorder 0 trials
- Pseudo-TORCH syndrome 2 0 trials
- Trichohepatoenteric syndrome 0 trials Sub-types →
-
TREX1-related type 1 interferonopathy 0 trials · 5 incl. sub-types
3 sub-types
-
ADAR-related type 1 interferonopathy 0 trials · 1 incl. sub-types
2 sub-types
- Dyschromatosis symmetrica hereditaria 1 trial
- Aicardi-Goutieres syndrome 6 0 trials
-
2 sub-types
- Aicardi-Goutieres syndrome 7 0 trials
- Singleton-Merten syndrome 1 0 trials
-
1 sub-type
- Aicardi-Goutieres syndrome 4 0 trials
-
1 sub-type
- Aicardi-Goutieres syndrome 2 0 trials
-
1 sub-type
- Aicardi-Goutieres syndrome 3 0 trials
-
1 sub-type
- Aicardi-Goutieres syndrome 9 0 trials
-
2 sub-types
- Aicardi-Goutieres syndrome 5 0 trials
- Chilblain lupus 2 0 trials
Most studied deeper sub-types
-
New pill aims to tame rare immune diseases
Disease control OngoingThis early-stage trial tests an experimental drug called BI 3000202 in 16 adults with rare type 1 interferonopathies, such as Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the drug is safe and how…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
Disease control CancelledThis phase 2 trial is testing whether combining an experimental drug called S-531011 with a precise radiation technique known as RadScopal can help control metastatic colorectal cancer that has not responded to prior treatments. The study enrolls about 30 adults with advanced dis…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Breathing in xenon: a new MRI scan to see lung damage?
Knowledge-focused OngoingThis study at Duke University tests whether a special MRI scan using inhaled xenon gas can detect changes in lung function over time in people with progressive pulmonary fibrosis. Sixty adults with various types of lung scarring will have MRI scans before starting anti-fibrotic m…
Phase 2 • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC